Log in to save to my catalogue

Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-relate...

Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-relate...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a43e4d1fdb674d64bed3cf237bf2c36f

Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events

About this item

Full title

Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events

Publisher

England: BMJ Publishing Group Ltd

Journal title

Journal for immunotherapy of cancer, 2023-06, Vol.11 (6), p.e006814

Language

English

Formats

Publication information

Publisher

England: BMJ Publishing Group Ltd

More information

Scope and Contents

Contents

BackgroundManagement of immune-related adverse events (irAEs) is important as they cause treatment interruption or discontinuation, more often seen with combination immune checkpoint inhibitor (ICI) therapy. Here, we retrospectively evaluated the safety and effectiveness of anti-interleukin-6 receptor (anti-IL-6R) as therapy for irAEs.MethodsWe per...

Alternative Titles

Full title

Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_a43e4d1fdb674d64bed3cf237bf2c36f

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a43e4d1fdb674d64bed3cf237bf2c36f

Other Identifiers

ISSN

2051-1426

E-ISSN

2051-1426

DOI

10.1136/jitc-2023-006814

How to access this item